Mineralys Therapeutics (MLYS) Other Working Capital Changes (2022 - 2026)

Mineralys Therapeutics has reported Other Working Capital Changes for 5 years, with the latest figure at $1.9 million in Q1 2026.

• Quarterly Other Working Capital Changes fell 55.69% year-over-year to $1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.9 million (down 235.86% YoY) and the FY2025 annual result came in at -$2.5 million, up 49.95% from the prior year.
• Other Working Capital Changes improved to $1.9 million in Q1 2026 per MLYS's latest filing, from -$1.6 million in the prior quarter.
• Over five years, Other Working Capital Changes peaked at $4.4 million in Q1 2025 and troughed at -$4.2 million in Q1 2024.
• A 5-year average of $371352.9 and a median of $532000.0 in 2022 frame the typical range for Other Working Capital Changes.
• The sharpest annual moves came in 2023 and 2024: Other Working Capital Changes jumped 7248.98% in 2023, then plunged 344.22% in 2024.
• Over 5 years, Other Working Capital Changes stood at $1.8 million in 2022, then tumbled by 30.84% to $1.2 million in 2023, then soared by 156.38% to $3.1 million in 2024, then plunged by 150.05% to -$1.6 million in 2025, then surged by 224.23% to $1.9 million in 2026.
• According to Business Quant data, Other Working Capital Changes over the past three periods registered $1.9 million, -$1.6 million, and -$3.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.